DuRvalumab with chEmotherapy as first line treAtment in advanced pleural Mesothelioma: A phase 3 randomised trial. The DREAM3R trial

被引：0
|
作者：
John, Thomas [1 ]
Forde, Patrick [2 ]
Kok, Peey Sei [3 ]
Brown, Chris [3 ]
Sun, Zhuoxin [4 ]
O'Byrne, Kenneth [5 ,6 ]
Yip, Sonia [3 ]
Anagnostou, Valasamo [7 ]
Cook, Alistair [8 ,9 ]
Lesterhuis, Willem J. [8 ]
Hughes, Brett G. M. [10 ,11 ]
Johnson, Lisa [12 ]
Oostendorp, Martijn [3 ]
Marinucci, Donna [12 ]
Fitzpatrick, Karen [12 ]
Ford, Kate [3 ]
Pavlakis, Nick [13 ,14 ]
Brahmer, Julie [2 ]
Stockler, Martin R. [3 ]
Ramalingam, Suresh [15 ]
Nowak, Anna [8 ,9 ,16 ]
机构：
[1] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Vic, Australia
[2] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[3] Univ Sydney, Nhmrc Clin Trials Ctr, Camperdown, NSW, Australia
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Princess Alexandra Hosp, Brisbane, Qld, Australia
[6] Queensland Univ Technol, Brisbane, Qld, Australia
[7] Johns Hopkins Univ, Bloomberg Kimmel Inst Canc Immunotherapy, Baltimore, MD USA
[8] Univ Western Australia, Natl Ctr Asbestos Related Dis, Perth, WA, Australia
[9] Univ Western Australia, Med Sch, Perth, WA, Australia
[10] Prince Charles Hosp, Canc Care Serv, Brisbane, Qld, Australia
[11] Univ Queensland, Brisbane, Qld, Australia
[12] PrECOG, Philadelphia, PA USA
[13] Northern Canc Inst, Sydney, NSW, Australia
[14] Univ Sydney, Sydney, NSW, Australia
[15] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[16] Sir Charles Gairdner Hosp, Med Oncol, Perth, WA, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
404
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [41] FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions
    Spira, A. I.
    Cho, B. C.
    Felip, E.
    Garon, E. B.
    Goto, K.
    Johnson, M. L.
    Leighl, N. B.
    Passaro, A.
    Planchard, D.
    Popat, S.
    Yang, J.
    Lu, X.
    Jiang, Y.
    Huang, J.
    Lam, M.
    Kowanetz, M.
    Wang, S.
    Le, J.
    Hsu, J. Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S339 - S339
  • [42] Publisher Correction: Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial
    Hai-Qiang Mai
    Qiu-Yan Chen
    Dongping Chen
    Chaosu Hu
    Kunyu Yang
    Jiyu Wen
    Jingao Li
    Ying-Rui Shi
    Feng Jin
    Ruilian Xu
    Jianji Pan
    Shenhong Qu
    Ping Li
    Chunhong Hu
    Yi-Chun Liu
    Yi Jiang
    Xia He
    Hung-Ming Wang
    Wan-Teck Lim
    Wangjun Liao
    Xiaohui He
    Xiaozhong Chen
    Zhigang Liu
    Xianglin Yuan
    Qi Li
    Xiaoyan Lin
    Shanghua Jing
    Yanju Chen
    Yin Lu
    Ching-Yun Hsieh
    Muh-Hwa Yang
    Chia-Jui Yen
    Jens Samol
    Hui Feng
    Sheng Yao
    Patricia Keegan
    Rui-Hua Xu
    Nature Medicine, 2022, 28 : 214 - 214
  • [43] Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ai, Xinghao
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    Qiu, Xiusong
    Gao, Jie
    Bao, Yuanyuan
    Liang, Liang
    Wang, Mengzhao
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (09) : 1512 - 1522
  • [44] Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial
    Zucali, P. A.
    Simonelli, M.
    De Vincenzo, F.
    Fatuzzo, G.
    Bertossi, M.
    Perrino, M.
    Miggiano, C.
    Giordano, L.
    Bonifacio, C.
    Sposta, F. Mrakic
    Santoro, A.
    ANNALS OF ONCOLOGY, 2015, 26 : 78 - 78
  • [45] A phase II clinical trial of the Vascular Disrupting Agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma
    Nowak, Anna K.
    Brown, Chris
    Millward, Michael J.
    Creaney, Jenette
    Byrne, Michael J.
    Hughes, Brett
    Kremmidiotis, Gabriel
    Bibby, David C.
    Leske, Annabell F.
    Mitchell, Paul L. R.
    Pavlakis, Nick
    Boyer, Michael
    Stockler, Martin R.
    LUNG CANCER, 2013, 81 (03) : 422 - 427
  • [46] BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)-Results from the ETOP 13-18 trial.
    Popat, Sanjay
    Felip, Enriqueta
    Dafni, Urania
    Pope, Anthony
    Perez, Susana Cedres
    Shah, Riyaz N. H.
    de Marinis, Filippo
    Smith, Laura Cove
    Caro, Reyes Bernabe
    Frueh, Martin
    Nackaerts, Kristiaan
    Greillier, Laurent
    Scherz, Amina
    Massuti, Bartomeu
    Schaer, Saemi
    Prince, Spasenija Savic
    Roschitzki-Voser, Heidi
    Ruepp, Barbara
    Peters, Solange
    Stahel, Rolf A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA8002 - LBA8002
  • [47] Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial
    Krug, Lee M.
    Kindler, Hedy L.
    Calvert, Hilary
    Manegold, Christian
    Tsao, Anne S.
    Fennell, Dean
    Ohman, Ronny
    Plummer, Ruth
    Eberhardt, Wilfried E. E.
    Fukuoka, Kazuya
    Gaafar, Rabab M.
    Lafitte, Jean-Jacques
    Hillerdal, Gunnar
    Chu, Quincy
    Buikhuisen, Wieneke A.
    Lubiniecki, Gregory M.
    Sun, Xing
    Smith, Margaret
    Baas, Paul
    LANCET ONCOLOGY, 2015, 16 (04): : 447 - 456
  • [48] AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
    Schumann, C.
    Heymach, J. V.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Galffy, G.
    Hochmair, M.
    Winder, T.
    Zukov, R.
    Garbaos, G.
    Gao, S.
    Kuroda, H.
    You, J.
    Lee, K. -Y.
    Antonuzzo, L.
    Aperghis, M.
    Doherty, G. J.
    Mann, H.
    Fouad, T. M.
    Reck, M.
    Weissinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 8 - 9
  • [49] A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: JME-001
    Fujimoto, N.
    Kozuki, T.
    Aoe, K.
    Miyamoto, Y.
    Wada, S.
    Harada, D.
    Yoshida, M.
    Sakurai, J.
    Hotta, K.
    ANNALS OF ONCOLOGY, 2020, 31 : S1077 - S1077
  • [50] JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
    Miyamoto, Yosuke
    Kozuki, Toshiyuki
    Aoe, Keisuke
    Wada, Sae
    Harada, Daijiro
    Yoshida, Michihiro
    Sakurai, Jun
    Hotta, Katsuyuki
    Fujimoto, Nobukazu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (10)
12345